Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2020-06-11 M&A Activity
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi och Selecta ingår strategiskt licensavtal för SEL-212, en ny, fas 3-klar behandling mot kronisk gikt
M&A Activity Classification · 99% confidence The document is a press release dated June 11, 2020, announcing a strategic licensing agreement between Sobi and Selecta Biosciences regarding the drug candidate SEL-212. It details financial terms, including upfront payments, equity purchases, milestone payments, and royalties. This type of announcement, which details a significant corporate transaction (licensing/partnership/financing), fits best under the 'Capital/Financing Update' category (CAP) as it involves substantial financial consideration and equity issuance, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. However, given the specific focus on the financial structure of the deal (upfront payments, stock purchase, milestones), 'CAP' is the most precise fit among the provided options, as it relates directly to capital structure changes and fundraising/deal structuring. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a detailed announcement of a major financial transaction, CAP is selected over the general RNS.
2020-06-11 Swedish
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Capital/Financing Update Classification · 95% confidence The document is a press release dated June 11, 2020, announcing a 'strategic licensing agreement' between Sobi and Selecta for a drug candidate (SEL-212). It details financial terms, including upfront payments, milestone payments, royalties, and a private placement of stock. This type of announcement, detailing a major business transaction (licensing/partnership) and associated financing/capital structure changes, fits best under the 'Capital/Financing Update' category, as it involves significant cash payments and stock purchase agreements between the companies. While it is a business development announcement, the explicit focus on the $100 million initial payment and the $25 million stock purchase makes CAP the most precise fit among the provided options, as it directly relates to capital movement and structure changes resulting from the deal. It is not a standard earnings release (ER), interim report (IR), or annual report (10-K).
2020-06-11 English
Kommuniké från Swedish Orphan Biovitrums (”Sobi”) årsstämma
AGM Information Classification · 99% confidence The document is explicitly titled "Kommuniké från Swedish Orphan Biovitrums ('Sobi') årsstämma" (Communiqué from Swedish Orphan Biovitrum's Annual General Meeting). It details the decisions made by shareholders regarding the approval of financial statements, election of the board, remuneration guidelines, changes to the articles of association, and approval of long-term incentive programs. These are all core activities of an Annual General Meeting (AGM). Although it is a summary/press release, the content directly relates to the outcomes of the AGM, making 'AGM Information' (AGM-R) the most appropriate classification, as it represents materials shared during or immediately following the AGM.
2020-05-13 Swedish
Bulletin from Swedish Orphan Biovitrum’s (“Sobi”) Annual General Meeting (AGM)
AGM Information Classification · 100% confidence The document is explicitly titled "Bulletin from Swedish Orphan Biovitrum's ('Sobi') Annual General Meeting (AGM)". It details the resolutions voted upon and approved during the AGM, such as the adoption of financial statements, election of the Board of Directors, approval of remuneration principles, and authorization for share issuance/incentive programs. This content directly corresponds to the definition of AGM Information.
2020-05-13 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Sobi (Swedish Orphan Biovitrum AB) for the first quarter of 2020. It contains detailed financial statements, management commentary, business segment analysis, and operational updates. It is clearly an interim financial report, not an announcement or a summary, as it provides extensive financial data and analysis for the specified period. Q1 2020
2020-04-29 Swedish
Earnings Release 2020
Earnings Release Classification · 99% confidence The document provides detailed financial performance metrics for the period 'January—March' (Q1 2020), including Total revenue, EBITA, EPS, and specific product sales figures (Elocta, Alprolix, Synagis, etc.). It includes a 'Financial summary' table comparing Q1 2020 results with Q1 2019 and provides a CEO statement and business review for the first quarter. The presence of detailed, period-specific financial results, comparative data, and management commentary strongly indicates a comprehensive quarterly financial report. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is comprehensive, not just highlights, and it is not a full Annual Report (10-K) as it covers only one quarter. Q1 2020
2020-04-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.